Skip to Main Content

Author Details

Theresa Y MacDonald
Caryl and Israel Englander Institute for Precision Medicine
2010
29
24
PMIDPaper TitleJournal TitlePublished Year
35050902Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.JCI Insight2022
35050902Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.JCI Insight2022
32493417Fusions involving BCOR and CREBBP are rare events in infiltrating glioma.Acta Neuropathol Commun2020
32493417Fusions involving BCOR and CREBBP are rare events in infiltrating glioma.Acta Neuropathol Commun2020
31592503Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.JCO Precis Oncol2019
31592503Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.JCO Precis Oncol2019
30068710SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.Clin Cancer Res2018
30068710SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.Clin Cancer Res2018
28762374Molecular alterations in prostate cancer and association with MRI features.Prostate Cancer Prostatic Dis2017
28762374Molecular alterations in prostate cancer and association with MRI features.Prostate Cancer Prostatic Dis2017
27498061Characterization of the leiomyomatous variant of myofibroblastoma: a rare subset distinct from other smooth muscle tumors of the breast.Hum Pathol2016
27728805N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.Cancer Cell2016
27498061Characterization of the leiomyomatous variant of myofibroblastoma: a rare subset distinct from other smooth muscle tumors of the breast.Hum Pathol2016
27728805N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.Cancer Cell2016
25877206MAGI3-AKT3 fusion in breast cancer amended.Nature2015
25877206MAGI3-AKT3 fusion in breast cancer amended.Nature2015
26181256Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.JAMA Oncol2015
26181256Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.JAMA Oncol2015
24457083Diagnostic utility of MYC amplification and anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites.Hum Pathol2014
25415230The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.Nat Commun2014
25420520ERG induces taxane resistance in castration-resistant prostate cancer.Nat Commun2014
24457083Diagnostic utility of MYC amplification and anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites.Hum Pathol2014
25217885MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features.Hum Pathol2014
25201530Organoid cultures derived from patients with advanced prostate cancer.Cell2014
25128228Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.Hum Pathol2014
24563616SPOP mutations in prostate cancer across demographically diverse patient cohorts.Neoplasia2014
25056375Evidence for molecular differences in prostate cancer between African American and Caucasian men.Clin Cancer Res2014
25420520ERG induces taxane resistance in castration-resistant prostate cancer.Nat Commun2014
25415230The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.Nat Commun2014
25201530Organoid cultures derived from patients with advanced prostate cancer.Cell2014
25217885MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features.Hum Pathol2014
25056375Evidence for molecular differences in prostate cancer between African American and Caucasian men.Clin Cancer Res2014
25128228Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.Hum Pathol2014
24563616SPOP mutations in prostate cancer across demographically diverse patient cohorts.Neoplasia2014
22981675Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.Eur Urol2013
22981675Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.Eur Urol2013
23358695Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.Neoplasia2013
23622249Punctuated evolution of prostate cancer genomes.Cell2013
23622249Punctuated evolution of prostate cancer genomes.Cell2013
23358695Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.Neoplasia2013
22610119Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.Nat Genet2012
22615383Oncogene-mediated alterations in chromatin conformation.Proc Natl Acad Sci U S A2012
22610119Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.Nat Genet2012
23091298Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes.Blood2012
23169519Challenges in recognizing treatment-related neuroendocrine prostate cancer.J Clin Oncol2012
23169519Challenges in recognizing treatment-related neuroendocrine prostate cancer.J Clin Oncol2012
23091298Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes.Blood2012
22615383Oncogene-mediated alterations in chromatin conformation.Proc Natl Acad Sci U S A2012
20975660Testing mutual exclusivity of ETS rearranged prostate cancer.Lab Invest2011
22389870Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.Cancer Discov2011
  • 1 - 50 of 58

Recommended Authors

Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2017
Number of shared co-authors 47
Niedzica Camacho
Memorial Sloan Kettering Cancer Center
Career Start Year 2013
Number of shared co-authors 3
Joshua Armenia
Oncology R&D
Career Start Year 2013
Number of shared co-authors 32
Martina Kluth
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 2012
Number of shared co-authors 0
Dan R Robinson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2011
Number of shared co-authors 45
Julie Livingstone
University of California los angeles
Career Start Year 2011
Number of shared co-authors 7
Matti Annala
University of British Columbia
Career Start Year 2011
Number of shared co-authors 9
Adam G Sowalsky
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 15
Gunes Gundem
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 9
David A Quigley
University of California-San Francisco
Career Start Year 2008
Number of shared co-authors 12
Alexander W Wyatt
University of British Columbia
Career Start Year 2007
Number of shared co-authors 22
Robert J Lonigro
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2007
Number of shared co-authors 42
Roula Albadine
Centre hospitalier de l'Universite de Montreal
Career Start Year 2006
Number of shared co-authors 0
Christina M??ller-Koop
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 2006
Number of shared co-authors 0
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 31
Tamara L Lotan
Johns Hopkins University School of Medicine
Career Start Year 2006
Number of shared co-authors 35
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 23
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 4
Sherri Z Millis
Foundation Medicine Inc
Career Start Year 2003
Number of shared co-authors 0
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 52
Maryou B Lambros
The Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 20
Luciano G Martelotto
Monash University
Career Start Year 2000
Number of shared co-authors 2
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Career Start Year 1999
Number of shared co-authors 48
Claudia Hube-Magg
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 1997
Number of shared co-authors 0
Ronald Simon
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 1996
Number of shared co-authors 6
Yi-Mi Wu
University of Michigan Medical School ann arbor
Career Start Year 1995
Number of shared co-authors 44
Siraj M Ali
Foundation Medicine
Career Start Year 1995
Number of shared co-authors 6
Yong-Jie Lu
Barts Cancer Institute, Queen Mary University of London
Career Start Year 1993
Number of shared co-authors 1
Rosina T Lis
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 45
Jeffrey S Ross
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 16

Collaborators

Mark A Rubin
University of Bern
Co-authored papers 29
Juan Miguel Mosquera
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 22
Kyung Park
New York University Langone Health
Co-authored papers 15
Andrea Sboner
Institute for Computational Biomedicine
Co-authored papers 13
Francesca Demichelis
University of Trento
Co-authored papers 12
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 12
Ashutosh K Tewari
Co-authored papers 8
Brian D Robinson
Sandra and Edward Meyer Cancer Center
Co-authored papers 8
Christopher E Barbieri
Weill Cornell Medical College
Co-authored papers 8
Olivier Elemento
Meyer Cancer Center
Co-authored papers 8
David S Rickman
Meyer Cancer Center
Co-authored papers 7
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Co-authored papers 7
David M Nanus
Sandra and Edward Meyer Cancer Center
Co-authored papers 7
Naoki Kitabayashi
Co-authored papers 5
Jacqueline Fontugne
Institut Curie, CNRS, PSL Research University
Co-authored papers 5
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 5
Zhengming Chen
Weill Cornell Medicine and New York Presbyterian Hospital
Co-authored papers 4
Myriam Kossai
INSERM, Universite Clermont Auvergne
Co-authored papers 4
Holger Moch
University Hospital Zurich
Co-authored papers 3
Shaham Beg
New York-Presbyterian Hospital-Weill Cornell Medical College
Co-authored papers 3
Stacey Gabriel
Broad Institute of MIT and Harvard
Co-authored papers 3
Scott L Carter
Co-authored papers 3
Mirjam Blattner
Co-authored papers 3
Robert C Onofrio
The Broad Institute of Harvard and MIT
Co-authored papers 3
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 3
Alex H Ramos
Co-authored papers 3
David Wilkes
Caryl and Israel Englander Institute for Precision Medicine.
Co-authored papers 3
Matthew Meyerson
Broad Institute
Co-authored papers 3
Mark Gerstein
Yale University
Co-authored papers 3
Raquel Esgueva
Co-authored papers 3
Release 1.2